

M. GIRALDEZ, L. VALDEOLMILLOS, E. MATEO, C. GARCIA PASTOR, M.E. RODRIGUEZ-RUIZ

BACKGROUND

Entrectinib is an oral, CNS-active, potent inhibitor of tyrosine approved for use in patients with ROS1-positive non-small cell lung cancer and NTRK gene fusion-positive solid tumors.

AIM AND OBJETIVES

To asses the safety and efficacy of entrectinib in Patient with recurrent central neurocytoma

MATERIAL AND METHODS


- Case report
- Observational study of clinical case

Data collection : Diagnostic and follow-up tests and therapy were obtained by the review of medical records.

- ✓ **Efficay evaluation:** magnetic resonance imaging
- ✓ **Entrectinib safety:**
 - Cardiac stress magnetic resonance imaging (MRI) with adenosine: Subclinical cardiotoxicity.
 - Neurologist and Psychiatry evaluation: psychotic episodes and organic mental disorder.

RESULTS


A 47-year-old female patient, no relevant medical history. Brain MRI diagnostic of ependymoma



July 2020: Diagnostic



September 2022: Stable disease



CONCLUSION AND RELEVANCE

- Entrectinib has shown to be active against those gene fusions in a primary CNS disease.
- Entrectinib is still associated with severe adverse events that require mandatory pharmacovigilance in our pharmacist daily practice.

